Refresher....2020 Clinical Guidance*Reported 2019:✓ TACTI-002 to...

Refresher....

2020 Clinical Guidance*
Reported 2019:
✓ TACTI-002 to commence, Phase II trial in
collaboration with MSD: H1 2019
✓ IMP761 program update: 2019
✓ INSIGHT-004 to commence, IIT Phase I trial in
collaboration with Pfizer and Merck KGaA: Q2
2019
✓ AIPAC fully recruited: Q2 2019
✓ TACTI-002 first data in September 2019
✓ TACTI-mel final efficacy data: Q4 2019
✓ TACTI-002 data update: Q4 2019
✓ INSIGHT-004 update: Q4 2019
Upcoming Data 2020 (est):
• MBC - mature, robust PFS & ORR data from AIPAC: Q1
2020 (March)
• NSCLC 1st line - more data from Stages 1 and 2 from TACTI002 throughout 2020 (e.g. German Cancer Congress
February 2020)
• HNSCC 2nd line - initial data from Stages 1 and 2 from
TACTI-002 throughout 2020 (e.g. AACR April 2020)
• NSCLC 2nd line - initial data from Stage 1 from TACTI-002
throughout 2020
• Combination with avelumab - initial data from Phase I trial
throughout 2020
*The actual timing of future data readouts may differ from expected timing shown
above. These dates are provided on a calendar year basis...